Lupin Ltd.

LUPIN

₹1840.7

2.24% (40.35)

Market Cap

₹83,886 Cr.

P/E

43.82

About

Lupin Limited is a global pharmaceutical company that specializes in developing, producing, and marketing a variety of branded and generic medicines, biotechnology products, and active pharmaceutical … Read more

Lupin Limited is a global pharmaceutical company that specializes in developing, producing, an… Read more

Low

972

52W Range

High

1850

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

12 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

13.4%

3yr Average

1.42%

5yr Average

2.19%

Net Profit Margin

Latest

9.57%

3yr Average

0.95%

5yr Average

1.82%

ROCE

Latest

17.99%

3yr Average

5.37%

5yr Average

8.04%

Debt to Equity

Latest

0.19

3yr Average

0.28

5yr Average

0.34

Market Share

7.98 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

3.08 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.03 %

(as of May 19)

Historic

Anti-Malarial - Market Share

0.09 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

2.15 %

(as of Nov 21)

Historic

Blood Related - Market Share

6.74 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.24 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.48 %

(as of Nov 21)

Historic

Endocrinology - Market Share

2.48 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

3.06 %

(as of Nov 21)

Historic

Gynecology - Market Share

3.13 %

(as of Nov 21)

Historic

Neurological - Market Share

1.70 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

2.06 %

(as of Nov 21)

Historic

Pain - Market Share

3.50 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

6.35 %

(as of Nov 21)

Historic

Respiratory - Market Share

0.46 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.23 %

(as of Nov 21)

Historic

Stomatological - Market Share

18.70 %

(as of Mar 21)

Source/Historic

Thyroid Hormone(Levothyroxine) - Market Share

3.39 %

(as of Nov 21)

Historic

Urology - Market Share

0 %

(as of Jul 22)

Historic

Vaccines - Market Share

1.49 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up

Acute vs Chronic

Operational Metrics

US DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Bharat Dynamics Ltd.
Navin Fluorine International Ltd.
Neuland Laboratories Ltd.
Borosil Renewables Ltd.
GMM Pfaudler Ltd.
Aarti Drugs Ltd.
Shaily Engineering Plastics Ltd.
Kilitch Drugs (India) Ltd.
Hindusthan National Glass & Industries Ltd.
Vivimed Labs Ltd.

Showing 5 of 10

FAQs on Lupin Ltd. Business

What does Lupin do?

Lupin Limited is a global pharmaceutical company known for its wide range of branded and generic formulations, biotechnology products, and APIs. It specializes in various therapy segments and is a leader in Anti-TB and Cephalosporins segments.

Who are the competitors of Lupin?

Lupin major competitors are Aurobindo Pharma, Mankind Pharma, Alkem Laboratories, Torrent Pharma, Abbott India, Dr. Reddy's Lab, Glaxosmithkline Phar.
Market Cap of Lupin is ₹83,886 Crs.
While the median market cap of its peers are ₹81,229 Crs.

Is Lupin financially stable compared to its peers?

Lupin seems to be less financially stable compared to its peers.
Altman Z score of Lupin is 7.62 and is ranked 7 out of its 8 competitors.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec